Lab Test

Paraneoplastic Autoantibody Evaluation, Serum

Test Codes

EPIC: LAB10022, Beaker: XPARANEOS, MAYO: PAVAL

Department

Send Outs

Specimen Collection Criteria

Collect: Two plain Red-top tubes.

Also acceptable: Two Gold-top SST tubes.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F) within 2 hours of collection.

Preparation for Courier Transport

Transport: 4.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 2.0 mL)

Rejection Criteria

  • Grossly lipemic specimens
  • Grossly Icteric specimens
  • Grossly hemolyzed specimens
  • Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F) within 2 hours of collection.

Transport: 4.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 2.0 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 28 days
Frozen (-20°C/-4°F or below): 28 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Mayo Medical Laboratories, Rochester, MN.

Performed

Varies
Results available in 11-18 days.

Reference Range

By report.

Test Methodology

Indirect Immunofluorescence Assay, Western Blot, Immunoblot, Radioimmunoassay, Cell-Binding Assay, Enzyme-Linked Immunosorbent Assay, Live-Cell Assay

Interpretation

By report.

Clinical Utility

Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer.

Paraneoplastic autoimmune neurological disorders reflect a patient's humoral and cellular immune responses to cancer. The cancer may be new or recurrent, is usually limited in metastatic volume, and is often occult by standard imaging procedures. Autoantibodies specific for onconeural proteins found in the plasma membrane, cytoplasm, and nucleus of neurons, glia, or muscle are generated in this immune response and serve as serological markers of paraneoplastic autoimmunity. Cancers recognized in this context most commonly are small-cell lung carcinoma, thymoma, ovarian (or related mullerian) carcinoma, breast carcinoma, and Hodgkin lymphoma. Pertinent childhood neoplasms recognized thus far include neuroblastoma, thymoma, Hodgkin lymphoma, and chondroblastoma. An individual patient's autoantibody profile can predict a specific neoplasm with 90% certainty, but not the neurological syndrome.

CPT Codes

86255 x9, 83519 x4, 83520

Add the following as appropriate for reflexes/confirmations performed:

83519-ARBI
83519-ARMO
84182-AGNBS
86255-AMPCS
86256-AMPIS
84182-AMIBS
84182-AN1BS
84182-AN2BS
86255-CS2CS
84182-CRMWS
86255-DPPCS
86256-DPPTS
86255-DPPIS
86255-GABCS
86256-GABIS
86341-GD65S
86255-LG1CS
86255-GL1CS
86256-GL1TS
86255-GL1IS
86255-NMDCS
86256-NMDIS
84182-PC1BS
84182-PCTBS 

Contacts

Last Updated

11/8/2024

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.